TODAY'S HEADLINES

Clear skin within reach for psoriasis patients

New data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx) produced long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis. Other major findings

Know these barriers to reduce type 2 diabetes costs

Low levels of adherence and persistence remain barriers to reducing the costs associated with type 2 diabetes in the United States, according to a report. Find out other major barriers to slashing diabetes costs. Read more

CONTINUING PHARMACY EDUCATION

Rheumatoid arthritis: partnering for optimal care

This month's CE activity, "Rheumatoid arthritis: partnering for optimal care," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat rheumatoid arthritis.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Lung cancer drug approved

FDA recently approved a new drug for patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Read more

October 26, 2016

Related Articles

FDA approves secukinumab for moderate-to-severe plaque psoriasis

Insurer diabetes program engages consumers, lowers costs